Latent TB Infection on World TB Day 2014

Elizabeth A. Talbot MDAssociate Professor, Deputy State EpiInfectious Disease & International HealthGeisel School of Medicine at Dartmouth

Latent TB Infection onWorld TB Day 2014

GEISELMED.DARTMOUTH.EDU

• World TB Day 2014– Relevant global and US

epidemiology• Top issues re: latent TB

infection (LTBI)– Testing: Interferon gamma

release assays (IGRAs) and tuberculin skin test (TST)

– Treatment options– Operational tidbits

Outline

GEISELMED.DARTMOUTH.EDU

• Number of new TB cases decreased to ~9M

– India+China 40%, Africa 24%– 13% co-infected with HIV

• 1.4 million people died from TB• Multi-drug resistant (MDR*) TB

– 3.7% among new cases– 20% among previously treated– 9% of MDR is XDRTB**

2013 Global Epi Snapshot

*MDR=resistance to H+R**XDR=MDR with resistance to FQ and injectable

GEISELMED.DARTMOUTH.EDU

• One-third of TB cases missed

• 50% of ~1.1 million new cases of HIV-related TB missed

• 75% with MDR-TB missed

“Missed” = gap between

estimated number who

became ill with TB and the

number notified to national TB

programs

GEISELMED.DARTMOUTH.EDU

2013 US Epi Snapshot

*MDR=resistance to H+R**XDR=MDR with resistanceTo FQ and injectable agent

GEISELMED.DARTMOUTH.EDU

GEISELMED.DARTMOUTH.EDU

PRIORITIZE LTBI TESTING FOR THOSE WITH RISK FACTORSFOR DEVELOPMENT OF TB

To control TB (and solve many of our testing dilemmas):

7

GEISELMED.DARTMOUTH.EDU

Most US TB is Reactivated LTBI• >80% of US TB is result of reactivated LTBI• Data from representative survey of US pop

showed 4.2% of persons screened 1999-2000 had LTBI

• Two risk categories for reactivation TB – LTBI prevalence is increased: e.g., foreign-born

persons– Rate of reactivation during LTBI is increased: e.g., HIV – Both risks are present: e.g., recent contact with case

• Nearly all these cases can be prevented by treatment of LTBI

Horsburgh & Rubin, NEJM 2011; 364 (154): 1441-8

GEISELMED.DARTMOUTH.EDU

Targeted Testing

• Identify, evaluate, and treat persons at high risk for – LTBI or – Progression LTBI to TB

• If you test for LTBI, have strategy to evaluate and treat those found to be infected– Local health

department is a resourceCDC Core Curriculum

GEISELMED.DARTMOUTH.EDU

High Risk for TB Exposure• Close contacts to TB

– HCWs who serve people at high risk for TB

• Persons who were born in or visit TB endemic areas– >40/100,000 population

• Persons who work or reside in high-risk congregate settings– Prisons, LTCFs, shelters

• Local populations at high risk for infection or disease– Drug users

Horsburgh & Rubin, NEJM 2011; 364 (154): 1441-8

GEISELMED.DARTMOUTH.EDU

High Risk for Progression from LTBI to Active TB

Plus, persons with certain other medical conditions:• Silicosis• Carcinoma of head or

neck• Gastrectomy or jejunoilial

bypassHorsburgh & Rubin, NEJM 2011; 364 (154): 1441-8

GEISELMED.DARTMOUTH.EDU

UNDERSTAND KEY FEATURES OF LTBI TESTING METHODS AND INTERPRETATION

For best (and credible) patient care:

GEISELMED.DARTMOUTH.EDU

Tuberculin Skin Test Do’s and Don’t’s

• Do TST– Prior to immunosuppression– 8–10 weeks after prior negative

TST for contact investigation• Health department does contact

investigations• Don’t test

– If previous positive result• Especially severe reaction

– <6 weeks after live virus vaccine• Can be done at same time as

vaccine• What if patient has history of

BCG* vaccination?– IGRA is preferred because no cross

reaction– But . . .

*BCG: TB vaccine derived from M. bovis, most commonly given vaccine worldwide!

GEISELMED.DARTMOUTH.EDU

Effect of BCG on TST reaction

• BCG given in infancy (age <2)– 23 studies with 78,846

vaccinees• 6.3% positive TST• 1% positive TST after

>10y• BCG given to older (age

>2)– 11 studies with 4,026

vaccinees• 40% positive TST due to

BCG• 20% positive TST after

>10y

Farhat, Menzies. Int J Tuberc Lung Dis 2006;10:1192-204

GEISELMED.DARTMOUTH.EDU

False Positive LTBI Testing Results

• Many persons who have positive screening result are at low risk for reactivation, and even the best screening test would identify many more false positive results than true positive results

• Quantitative test results can help– TST induration– IGRA values

• Patient considerations– Costs/risks/benefits of treating or not treating?

• Help patient weigh, be honest about uncertainties, advise

GEISELMED.DARTMOUTH.EDU

Do Which When?One is

Preferred• IGRAs

– History of BCG vaccination

– For those with low rates of return for TST reading

• Homeless, IVDA

• TST– Children <5

• When other unavailable

Both is Justifiable*

• When 1st test is neg, but risk for progression is high

• When 1st test is pos, but more evidence is needed to encourage compliance

• When IGRA is indeterminate, borderline or invalid

• If suspect 1st test is wrong

Neither is Preferred

• Recent contact to case– IGRA should be

repeated at 8-10 weeks (like TST)

– Data on timing of IGRA conversion not available

– IGRA may be more sensitive than TST

• Periodic screening (e.g., HCW)

*PPD may “boost” IGRA response. If you do TST then IGRA, do it within 7d of TST

GEISELMED.DARTMOUTH.EDU

UPDATES REGARDING LTBI TREATMENT

The goal is treating LTBI to control TB:

17

GEISELMED.DARTMOUTH.EDU

LTBI Treatment Regimens

Drugs Months of Duration Interval

Minimum

Doses

INH 9*Daily 270

2x wkly** 76

INH 6Daily 180

2x wkly** 52RIF*** 4 Daily 120

*Preferred; **Intermittent treatment only with DOT; ***Rifabutin can be substituted

GEISELMED.DARTMOUTH.EDU

Rifapentine (Priftin)

• Rifamycin derivative developed in 1950s, marketed 1998• Similar spectrum as rifampin, but with

longer half-life for weekly dosing• For active TB treatment

– Higher relapse rates• Difficulty complying with asynchronous regimen

– Drug-drug interactions HIV protease inhibitors

– New clinical trials underway for TB

GEISELMED.DARTMOUTH.EDU

PREVENT TB: INH & Rifapentine for 12wks

• INH for 9m vs. INH + RPT weekly for 12wks with DOT

• Study population: 8,000 patients– TST+ close contacts 70%– Converters 25%– TST+ HIV or HIV with close contact 2%– TST+ with fibrotic changes 2%

• Efficacy was similar – 0.19 v 0.43% developed TB disease

• Completion rate higher – 82 v 69%

• Cost higher $160 v $6, but may be cost-effective

GEISELMED.DARTMOUTH.EDU

RPT+INH clearly non-inferior to INH monotherapyMore pronounced in intention to treat analysis

GEISELMED.DARTMOUTH.EDU

Recommendations

• Equal alternative to 9m INH in ≥12y plus high risk for TB disease

– Close contact– Converter– Fibrotic changes on CXR– HIV not on ART, otherwise healthy

• Consider other patients on an individual basis

• Children 2-11y can be considered, especially if unlikely to complete 9m plus high risk to progress to TB disease

GEISELMED.DARTMOUTH.EDU

INH-RPT NOT Recommended

• Children < 2 years old• HIV on ART• Pregnancy, or likely to become

pregnant during treatment• Presumed INH or RIF resistance• Prior adverse reaction with INH or

rifamycin

GEISELMED.DARTMOUTH.EDU

Current LTBI Treatment Regimens

Drugs Months of Duration Interval

Minimum

Doses

INH 9*Daily 270

2x wkly** 76

INH 6Daily 180

2x wkly** 52RIF*** 4 Daily 120

INH-RPT 3 Weekly** 12

*Preferred; **Intermittent treatment only with DOT; ***Rifabutin can be substituted

GEISELMED.DARTMOUTH.EDU

GEISELMED.DARTMOUTH.EDU

• 65/90 contacts chose INH+RPT• DOT at school, calls/texts/visits• Treatment completion similar

– 94%-100% for 3 regimens• 4 did not complete HP; 1 each

– HA+nausea– Rash+dizziness– F+aches– Unknown

• “CDC collaborating with health departments and institutions for more data nationally”

Programmatic Use of INH+RPT

GEISELMED.DARTMOUTH.EDU

Summary

• TB remains a global threat• In US, treatment of LTBI is key TB control strategy• Diagnosis of LTBI should

– Target risk populations– Incorporate updated approaches using TST and

IGRAs• Treatment options for LTBI now include 12

dose rifapentine-INH regimen• State and local health departments offer up to

date epidemiology and medical consultation

THANK YOU!!And thanks to my trusted colleagues at NH DHHS for their encouragement and expertise